NCT01830127 - BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Ribavirin

24 Weeks

DRUG

BI 207127 high dose

24 Weeks

DRUG

Faldaprevir

24 Weeks

DRUG

Ribavirin

24 Weeks

DRUG

BI 207127 low dose

24 Weeks

DRUG

Faldaprevir

24 Weeks

Trial Locations (19)

Unknown

1241.30.10003 Boehringer Ingelheim Investigational Site, La Mesa

1241.30.10007 Boehringer Ingelheim Investigational Site, San Diego

1241.30.10001 Boehringer Ingelheim Investigational Site, DeLand

1241.30.10012 Boehringer Ingelheim Investigational Site, West Palm Beach

1241.30.10011 Boehringer Ingelheim Investigational Site, Arlington

1241.30.10002 Boehringer Ingelheim Investigational Site, Norfolk

1241.30.49002 Boehringer Ingelheim Investigational Site, Berlin

1241.30.49004 Boehringer Ingelheim Investigational Site, Berlin

1241.30.49005 Boehringer Ingelheim Investigational Site, Berlin

1241.30.49008 Boehringer Ingelheim Investigational Site, Bonn

1241.30.49006 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1241.30.49001 Boehringer Ingelheim Investigational Site, Hanover

1241.30.49003 Boehringer Ingelheim Investigational Site, Leipzig

1241.30.49007 Boehringer Ingelheim Investigational Site, Mainz

1241.30.34002 Boehringer Ingelheim Investigational Site, Barcelona

1241.30.34005 Boehringer Ingelheim Investigational Site, Barcelona

1241.30.34003 Boehringer Ingelheim Investigational Site, Madrid

1241.30.34001 Boehringer Ingelheim Investigational Site, Majadahonda (Madrid)

1241.30.44002 Boehringer Ingelheim Investigational Site, London